AMGN · Earnings call · 2026Q3T · Full report

Manufacturing Capacity Expansion

AMGEN INC · 2026-11-03 · Importance 40 · Surprise 42

Management said capacity expansion is designed to support larger quantities of protein rather than biosimilar production, and expressed confidence in Amgen's ability to remain a reliable supplier of high-quality biosimilars. The company described its expansion as supporting commercial growth and preparation for a potential MariTide launch. Investments included U.S. manufacturing sites in North Carolina, Ohio, and Puerto Rico.

Key facts

• Amgen said it was confident it could continue to reliably supply high-quality biosimilars and that capacity expansion was designed for larger quantities of protein than the biosimilar program required.